Sagimet Biosciences Inc. (SGMT)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch SGMT
See up to 3 months of SGMT. The 7-day demo opens the 1M and 3M ranges and puts SGMT on your watchlist.
Start 7-day demoLatest SGMT insider trades
About Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. files with the SEC under CIK 0001400118 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
SGMT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 464,633 | $4.51M |
| Option exercise | 8 | 742,386 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
SGMT insider transactions (Form 4)
4431 Form 4 filings on record, the earliest from Jun 9, 2025, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| George Kemble - Director | Option exercise | Series A Common Stock | 326,618 | $6.36 | $2.08M | |
| George Kemble - Director | Option exercise | Series A Common Stock | 24,369 | $6.36 | $155K | |
| George Kemble - Director | Open-market sale | Series A Common Stock | 350,987 | $10.23 footnote F2 | $3.59M | |
| George Kemble - Director | Option exercise | Stock Option (Right to Buy) | 326,618 | $0.00 | - | |
| George Kemble - Director | Option exercise | Stock Option (Right to Buy) | 24,369 | $0.00 | - | |
| ||||||
| George Kemble - Director | Option exercise | Series A Common Stock | 9,751 | $6.36 | $62K | |
| George Kemble - Director | Option exercise | Series A Common Stock | 10,455 | $6.36 | $66K | |
| George Kemble - Director | Open-market sale | Series A Common Stock | 20,206 | $9.95 footnote F2 | $201K | |
| George Kemble - Director | Option exercise | Stock Option (Right to Buy) | 9,751 | $0.00 | - | |
| George Kemble - Director | Option exercise | Stock Option (Right to Buy) | 10,455 | $0.00 | - | |
| ||||||
 David Happel - Officer | Open-market sale | Series A Common Stock | 64,051 | $7.76 footnote F2 | $497K | |
| ||||||
| Elizabeth Rozek - Officer | Open-market sale | Series A Common Stock | 10,545 | $7.76 footnote F2 | $82K | |
| ||||||
| George Kemble | Open-market sale | Series A Common Stock | 18,844 | $7.46 footnote F2 | $141K | |
| ||||||
| Beth C. Seidenberg - Director | Grant or award | Stock Option (Right to Buy) | 39,567 | $0.00 | - | |
| Paul W. Hoelscher - Director | Grant or award | Stock Option (Right to Buy) | 39,567 | $0.00 | - | |
 Jennifer Jarrett - Director | Grant or award | Stock Option (Right to Buy) | 39,567 | $0.00 | - | |
 Elizabeth A. Grammer - Director | Grant or award | Stock Option (Right to Buy) | 39,567 | $0.00 | - | |
| George Kemble - Director | Grant or award | Stock Option (Right to Buy) | 39,567 | $0.00 | - | |
| Anne M. Phillips - Director | Grant or award | Stock Option (Right to Buy) | 39,567 | $0.00 | - | |
| Thierry Chauche - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Andreas Grauer - Officer | Grant or award | Stock Option (Right to Buy) | 35,000 | $0.00 | - | |
| Elizabeth Rozek - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| David Happel - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Andreas Grauer - Officer | Grant or award | Stock Option (Right to Buy) | 264,759 | $0.00 | - | |
| Elizabeth Rozek - Officer | Grant or award | Series A Common Stock | 44,000 footnote F1 | $0.00 | - | |
| Elizabeth Rozek - Officer | Grant or award | Stock Option (Right to Buy) | 88,000 | $0.00 | - | |
| ||||||
| Eduardo Bruno Martins - Officer | Grant or award | Series A Common Stock | 44,000 footnote F1 | $0.00 | - | |
| Eduardo Bruno Martins - Officer | Grant or award | Stock Option (Right to Buy) | 88,000 | $0.00 | - | |
| ||||||
| David Happel - Officer | Grant or award | Series A Common Stock | 128,000 footnote F1 | $0.00 | - | |
| David Happel - Officer | Grant or award | Stock Option (Right to Buy) | 256,000 | $0.00 | - | |
| ||||||
| Thierry Chauche - Officer | Grant or award | Series A Common Stock | 44,000 footnote F1 | $0.00 | - | |
| Thierry Chauche - Officer | Grant or award | Stock Option (Right to Buy) | 88,000 | $0.00 | - | |
| ||||||
| David Happel - Officer | Open-market sale | Series A Common Stock | 12,101 | $5.36 | $65K | |
| Thierry Chauche - Officer | Open-market sale | Series A Common Stock | 1,312 | $5.36 | $7K | |
| Eduardo Bruno Martins - Officer | Open-market sale | Series A Common Stock | 3,640 | $5.36 | $20K | |
| Elizabeth Rozek - Officer | Open-market sale | Series A Common Stock | 2,622 | $5.36 | $14K | |
| George Kemble - Officer | Open-market sale | Series A Common Stock | 37,688 | $7.69 footnote F2 | $290K | |
| ||||||
| Elizabeth Rozek - Officer | Grant or award | Series A Common Stock | 9,855 footnote F1 | $0.00 | - | |
| Elizabeth Rozek - Officer | Grant or award | Stock Option (Right to Buy) | 13,367 | $0.00 | - | |
| ||||||
| David Happel - Officer | Open-market sale | Series A Common Stock | 65,478 | $9.13 | $598K | |
| Eduardo Bruno Martins - Officer | Open-market sale | Series A Common Stock | 8,277 | $9.13 | $76K | |
| Elizabeth Rozek - Officer | Open-market sale | Series A Common Stock | 10,780 | $9.13 | $98K | |
| Beth C. Seidenberg - Director | Grant or award | Stock Option (Right to Buy) | 28,522 | $0.00 | - | |
| Beth C. Seidenberg - Director | Grant or award | Stock Option (Right to Buy) | 32,250 | $0.00 | - | |
Item 7.01, 8.01, 9.01
Item 8.01
Item 2.02, 7.01, 9.01
Item 7.01, 9.01
Recent SGMT Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| GEORGE KEMBLE | Director | 350,987 | $3.26M | View on EDGAR | |
| GEORGE KEMBLE | Director | 20,206 | $193K |
SGMT insider trading FAQ
What is the latest insider trade for SGMT?
Sagimet Biosciences Inc. (SGMT) had 5 insider filings in the last 90 days, with the most recent on 2026-08-17. The full record for SGMT runs to 31 Form 4 filings, the earliest from 2025-06-09. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SGMT stock?
No insider purchases of SGMT were filed in the last 90 days.
How many insiders are selling SGMT stock?
5 insider sales of SGMT were filed in the last 90 days, totaling $4.51M.
Where can I see SGMT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SGMT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - George Kemble view on EDGAR
- - George Kemble view on EDGAR
- - David Happel view on EDGAR
- - Elizabeth Rozek view on EDGAR
- - George Kemble view on EDGAR
- - Beth C. Seidenberg view on EDGAR
- - Paul W. Hoelscher view on EDGAR
- - Jennifer Jarrett view on EDGAR
- - Elizabeth A. Grammer view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where SGMT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SGMT with a 7-day demo
- SGMT on your watchlist
- Every SGMT Form 4 filing on record
- Up to 3 months of SGMT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
